oblimersen profile

oblimersen: targets the Bcl-2 oncogene good efficacy with low toxicity tumour regressions [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	118984457
MeSH ID	M0362850

Synonym
190977-41-4
genasense
g 3139
augmerosen
oblimersen sodium [usan]
dna, d(p-thio)(t-c-t-c-c-c-a-g-c-g-t-g-c-g-c-c-a-t)
oblimersen sodium
g3139
oblimersen
unii-85j5zp6ysl
85j5zp6ysl ,
d-g3139

Excerpt	Reference	Relevance
"Oblimersen (G3139) is a phosphorothioate 18-mer antisense oligonucleotide directed against the first 6 BCL2 codons."	( Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Bloomfield, CD; Blum, W; Byrd, JC; Carroll, AJ; Eisfeld, AK; Jacobson, S; Kohlschmidt, J; Kolitz, JE; Larson, RA; Marcucci, G; Mrózek, K; Stock, W; Stone, RM; Stuart, RK; Sutamtewagul, G; Thakuri, M; Vij, R; Walker, AR; Wang, ES; Yin, J, 2021)	1.59
"Oblimersen sodium is a bcl-2 antisense oligonucleotide complementary to the first six codons of the open-reading frame of bcl-2 mRNA that can decrease transcription of Bcl-2 protein and increase myeloma cell susceptibility to cytotoxic agents."	( Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Callander, N; Chanan-Khan, AA; Christiansen, NP; Hohl, RJ; Jagannath, S; Lister, J; Niesvizky, R; Oken, M; Schiller, GJ; Zimmerman, TM, 2009)	1.32
"Oblimersen sodium is an antisense oligonucleotide compound designed to specifically bind to human bcl-2 mRNA, resulting in catalytic degradation of bcl-2 mRNA and subsequent decrease in bcl-2 protein translation."	( Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer. Frankel, SR; Herbst, RS, 2004)	2.49
"Oblimersen is a phosphorothioate antisense oligonucleotide complimentary to the Bcl-2 mRNA and a potent inhibitor of Bcl-2 expression which in pre-clinical testing can significantly enhance the therapeutic effect of chemotherapy, hormone and radiation therapy."	( Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer. Chi, KN, 2005)	1.37
"Oblimersen sodium is an antisense oligonucleotide to the first 6 codons of the B-cell leukemia gene 2 (bcl-2) open reading frame. "	( Early results of a phase I trial of oblimersen sodium for relapsed or refractory Waldenstrom's macroglobulinemia. Badros, A; Erlichman, C; Gertz, MA; Geyer, SM; Kahl, BS, 2005)	2.05
"Oblimersen is an 18-base oligodeoxynucleotide encoding antisense to the gene for bcl-2, an anti-apoptotic protein that is upregulated in renal and other cancers. "	( Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. Baratta, T; Diamond, DJ; Dutcher, JP; Frankel, P; Gandara, DR; Lacey, SF; Lara, P; Margolin, K; Quinn, DI; Synold, TW; Xi, B, 2007)	3.23
"Oblimersen (Genasense is a Bcl-2 antisense compound that selectively targets Bcl-2 RNA for degradation by RNase H and thereby decreases Bcl-2 protein production. "	( Oblimersen in the treatment of metastatic melanoma. Kirkwood, JM; Tarhini, AA, 2007)	3.23
"Oblimersen is an antisense oligonucleotide developed by Genta for systemic use as an injection. "	( Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium. , 2007)	3.23
"Oblimersen is a 18-mer phosphorothioate antisense oligonucleotide designed to bind to the first six codons of the human bcl-2 mRNA."	( Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality. Moreira, JN; Santos, A; Simões, S, 2006)	1.33

Excerpt	Reference	Relevance
"Oblimersen was shown to increase in vitro and in vivo effect of RT on SCLC cell lines. "	( Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response. Bourhis, J; Brown, BD; Deutsch, E; Loriot, Y; Mordant, P; Soria, JC, 2010)	2.04
"Oblimersen should also enhance the cytotoxic effect of chemotherapy in WM."	( Early results of a phase I trial of oblimersen sodium for relapsed or refractory Waldenstrom's macroglobulinemia. Badros, A; Erlichman, C; Gertz, MA; Geyer, SM; Kahl, BS, 2005)	1.32

Excerpt	Reference	Relevance
"Pretreatment with oblimersen followed by cyclophosphamide (Cytoxan, Neosar) markedly improved survival relative to single-agent cyclophosphamide in a murine xenograft model."	( Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma. Klasa, RJ, 2004)	0.65

Excerpt	Reference	Relevance
"To evaluate the pharmacokinetic (PK) properties of Bcl-2 antisense oligodeoxynucleotide G3139 when combined with the anthracycline anticancer drug doxorubicin (DOX) in a model of MDA435/LCC6 human breast cancer in severely compromised immunodeficient (SCID) mice."	( Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. Lopes de Menezes, DE; Mayer, LD, 2002)	0.31
" at 5 mg/kg revealed a biexponential plasma concentration-time curve with a Cmax of 99."	( Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. Lopes de Menezes, DE; Mayer, LD, 2002)	0.31
"To assess the feasibility of administering oblimersen sodium, a phosphorothioate antisense oligonucleotide directed to the Bcl-2 mRNA, with docetaxel to patients with hormone-refractory prostate cancer; to characterize the pertinent pharmacokinetic parameters, Bcl-2 protein inhibition in peripheral blood mononuclear cell(s) (PBMC) and tumor; and to seek preliminary evidence of antitumor activity."	( A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Bushnell, D; Fingert, H; Hammond, LA; Izbicka, E; Kreisberg, J; Kuhn, J; Malik, S; Patnaik, A; Rowinsky, EK; Schwartz, G; Smetzer, L; Thompson, I; Tolcher, AW, 2004)	0.83
" Plasma was sampled to characterize the pharmacokinetic parameters of both oblimersen and docetaxel, and Bcl-2 protein expression was measured from paired collections of PBMCs pretreatment and post-treatment."	( A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Bushnell, D; Fingert, H; Hammond, LA; Izbicka, E; Kreisberg, J; Kuhn, J; Malik, S; Patnaik, A; Rowinsky, EK; Schwartz, G; Smetzer, L; Thompson, I; Tolcher, AW, 2004)	0.79
"To determine the antitumor activity and safety of oblimersen sodium, a phosphorothioate antisense oligonucleotide directed to the bcl-2 mRNA, with docetaxel in patients with hormone-refractory prostate cancer (HRPC) and to determine if relevant pharmacokinetic and pharmacodynamic variables of oblimersen or docetaxel influence response to this therapy."	( A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Berg, K; Chi, K; D'Aloisio, S; Frankel, SR; Gleave, M; Izbicka, E; Kuhn, J; Murray, N; Patnaik, A; Rowinsky, E; Schwartz, G; Takimoto, C; Thompson, I; Tolcher, AW, 2005)	0.82
" Plasma samples were analyzed to characterize the pharmacokinetic variables of both oblimersen and docetaxel, and paired collections of peripheral blood mononuclear cells were collected to determine Bcl-2 protein expression pretreatment and post-treatment."	( A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Berg, K; Chi, K; D'Aloisio, S; Frankel, SR; Gleave, M; Izbicka, E; Kuhn, J; Murray, N; Patnaik, A; Rowinsky, E; Schwartz, G; Takimoto, C; Thompson, I; Tolcher, AW, 2005)	0.79
"To assess the feasibility and antitumor activity of oblimersen sodium, an antisense oligonucleotide directed to the Bcl-2 mRNA, combined with irinotecan in patients with advanced colorectal carcinoma, characterize the pharmacokinetic behavior of both oblimersen sodium and irinotecan, and examine Bcl-2 protein inhibition in peripheral blood mononuclear cells (PBMC)."	( A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer. Berg, K; Hammond, LA; Izbicka, E; Kuhn, J; Mita, MM; Ochoa, L; Patnaik, A; Rowinsky, EK; Schwartz, G; Tolcher, AW; Yeh, IT, 2006)	0.83
" In striking contrast, PEGylation of 1 resulted in dramatically improved pharmacokinetic profiles in vivo, with a prolonged half-life (t1/2), increased plasma concentration, and increased area under the plasma concentration-time curve (AUC)."	( Delivery of G3139 using releasable PEG-linkers: impact on pharmacokinetic profile and anti-tumor efficacy. Benimetskaya, L; Borchard, G; Borowski, V; Lipman, J; Longley, C; Mehlig, M; Peng, P; Reddy, P; Stein, CA; Xia, J; Zhang, Y; Zhao, H, 2007)	0.34
" The pharmacokinetic interactions between G3139 and carboplatin/paclitaxel were measured."	( A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors. Alberti, D; Eickhoff, J; Kolesar, J; Lee, F; Leith, C; Liu, G; Marnocha, R; McNeel, DG; Schell, K; Traynor, A; Wilding, G; Zwiebel, J, 2008)	0.35
" The half-life of G3139 and its metabolites was observed at 31 and 68 h, respectively."	( Evaluation of Pharmacokinetics and Metabolism of Phosphorothioate Antisense Oligonucleotide G3139 in Rat by Capillary Electrophoresis with Laser-Induced Fluorescence. Ban, E; Kwon, H; Song, EJ, 2021)	0.62

Excerpt	Reference	Relevance
" This study investigated the activity of the Bcl-2 antisense oligodeoxynucleotide (AS ODN) G3139 combined with free doxorubicin (F-DOX) or sterically stabilized liposomal doxorubicin (SL-DOX) to determine the role that drug pharmacodistribution properties may have on antitumor activity using a Bcl-2-expressing human breast solid tumor xenograft model."	( Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Hudon, N; Lopes de Menezes, DE; Mayer, LD; McIntosh, N, 2000)	0.31
"To evaluate the pharmacokinetic (PK) properties of Bcl-2 antisense oligodeoxynucleotide G3139 when combined with the anthracycline anticancer drug doxorubicin (DOX) in a model of MDA435/LCC6 human breast cancer in severely compromised immunodeficient (SCID) mice."	( Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. Lopes de Menezes, DE; Mayer, LD, 2002)	0.31
"These findings indicate that drug-drug interactions between G3139 and DOX are modest and favorable in that elevated tumor DOX levels are achieved without compromising G3139 tumor uptake or significantly altering plasma drug concentrations."	( Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. Lopes de Menezes, DE; Mayer, LD, 2002)	0.31
" The objective of this work was to investigate the antitumor efficacy of the Bcl-2 antisense oligonucleotide oblimersen (Genasense; G3139), alone and in combination with vinorelbine (VNB), in an ectopic and orthotopic xenograft model of NCI-H460 human non-small-cell lung cancer."	( Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer. Bally, MB; Bebb, G; Hu, Y; Mayer, LD; Ng, R; Sartor, JR; Tan, S; Yan, H, 2004)	0.85
" Results showed a reduced sensitivity of melanoma cells to gimatecan following Bcl-2 transfection and inversely, increased cell sensitivity to gimatecan in combination with oblimersen."	( Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts. Balsari, A; Carenini, N; De Cesare, M; Del Bufalo, D; Perego, P; Pratesi, G; Righetti, SC; Rivoltini, L; Zunino, F; Zupi, G, 2005)	0.52
" In contrast, G3139 treatment (25 mg/kg every 3 days x 5 starting on day 7) in combination with CDDP (8 mg/kg on day 14) completely abrogated tumor engraftment in 80% of animals compared to CDDP (0%) or CDDP + control oligo (0%)."	( Systemic Bcl-2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV+ nasopharyngeal carcinoma xenografts in SCID mice. Carbone, R; Cheng, YC; Grill, S; Lacy, J; Loomis, R; Srimatkandada, P, 2006)	0.33
" We evaluated the efficacy and safety of oblimersen combined with GO in patients > or =60 years of age in first relapse with CD33+ acute myeloid leukemia."	( A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Giles, F; Kalaycio, M; Kolitz, J; Marcucci, G; Moore, J; Seiter, K; Stock, W; Zenk, D, 2006)	0.87
"To determine the maximum-tolerated dose, toxicity, pharmacokinetics, and biologic effects of G3139 when administered with doxorubicin and cyclophosphamide to children with relapsed solid tumors."	( Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study. Adamson, PC; Blaney, SM; Chandula, R; Hogarty, MD; Krailo, MD; Rheingold, SR; Sauk-Schubert, C; Zwiebel, JA, 2007)	0.34
"This phase I trial assessed the safety and tolerability of G3139 when given in combination with carboplatin and paclitaxel chemotherapy."	( A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors. Alberti, D; Eickhoff, J; Kolesar, J; Lee, F; Leith, C; Liu, G; Marnocha, R; McNeel, DG; Schell, K; Traynor, A; Wilding, G; Zwiebel, J, 2008)	0.35
" This multicentric phase I study was carried out to evaluate maximum tolerated dose (MTD), safety and preliminary efficacy of oblimersen in combination with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment (NST) in primary breast cancer (PBC)."	( Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study. Eichbaum, M; Eiermann, W; Kaufmann, M; Marmé, F; Rom, J; Scharf, A; Schlehe, B; Schneeweiss, A; Schuetz, F; Sievert, M; Sinn, HP; Sohn, C; von Minckwitz, G, 2008)	1.99
"Previously untreated patients with PBC T2-4a-c N0-3 M0 received one cycle of docetaxel 75 mg/m(2), adriamycin 50 mg/m(2) and cyclophosphamide 500 mg/m(2) administered on day 5 combined with escalating doses of oblimersen as a 24-h continuous infusion on days 1-7 followed by five cycles of combination of docetaxel, adriamycin and cyclophosphamide (TAC) without oblimersen every 3 weeks."	( Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study. Eichbaum, M; Eiermann, W; Kaufmann, M; Marmé, F; Rom, J; Scharf, A; Schlehe, B; Schneeweiss, A; Schuetz, F; Sievert, M; Sinn, HP; Sohn, C; von Minckwitz, G, 2008)	1.98
" Following oblimersen combined with TAC, the most severe toxicity was neutropenia [National Cancer Institute-Common Toxicity Criteria (NCI-CTC) grades 1-2/3/4] which developed in 0/0/56% of patients (cohort I), 11/0/56% of patients (cohort II) and 20/20/50% of patients (cohort III)."	( Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study. Eichbaum, M; Eiermann, W; Kaufmann, M; Marmé, F; Rom, J; Scharf, A; Schlehe, B; Schneeweiss, A; Schuetz, F; Sievert, M; Sinn, HP; Sohn, C; von Minckwitz, G, 2008)	2.18
"Oblimersen up to a dose of 7 mg/kg/day administered as a 24-h infusion on days 1-7 can be safely administered in combination with standard TAC on day 5 as NST in patients with PBC."	( Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study. Eichbaum, M; Eiermann, W; Kaufmann, M; Marmé, F; Rom, J; Scharf, A; Schlehe, B; Schneeweiss, A; Schuetz, F; Sievert, M; Sinn, HP; Sohn, C; von Minckwitz, G, 2008)	3.23
" In conclusion, oblimersen sodium can be safely combined with rituximab."	( Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Fayad, L; Hagemeister, F; Kwak, L; Leber, B; Lopez, A; McLaughlin, P; Pro, B; Rodriguez, A; Romaguera, J; Samaniego, F; Smith, M; Younes, A; Zwiebel, J, 2008)	0.98
"Preclinical data showed enhancement of breast cancer cell death when G3139 was combined with anthracyclines and taxanes."	( Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Booser, DJ; Brewster, AM; Buchholz, TA; Cristofanilli, M; Esteva, FJ; Hortobagyi, GN; Hunt, KK; Lipsanen, C; Madden, TL; Moulder, SL; Symmans, WF; Valero, V; Yuan, L; Zwiebel, J, 2008)	0.35
" for 5 days) in combination with AT."	( Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Booser, DJ; Brewster, AM; Buchholz, TA; Cristofanilli, M; Esteva, FJ; Hortobagyi, GN; Hunt, KK; Lipsanen, C; Madden, TL; Moulder, SL; Symmans, WF; Valero, V; Yuan, L; Zwiebel, J, 2008)	0.35
"G3139 in combination with doxorubicin and docetaxel is well tolerated."	( Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Booser, DJ; Brewster, AM; Buchholz, TA; Cristofanilli, M; Esteva, FJ; Hortobagyi, GN; Hunt, KK; Lipsanen, C; Madden, TL; Moulder, SL; Symmans, WF; Valero, V; Yuan, L; Zwiebel, J, 2008)	0.35
"To determine the maximum tolerated dose of oblimersen, an antisense oligonucleotide directed to the Bcl-2 mRNA, in combination with cisplatin and 5-flourouracil in patients with advanced gastric and esophageal carcinoma."	( A phase I trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma. Christos, P; Kaubisch, A; Ocean, AJ; Raab, R; Ramirez, M; Sparano, JA; Vinciguerra, V, 2010)	0.95
"Fifteen patients received a total of 49 courses of oblimersen at doses of 3, 5, or 7 mg/kg/d given as a 7 day CIVI in combination with 4 or 5 day CIVI of 5-FU (1000 or 750 mg/m2/d) plus intravenous cisplatin (100 or 75 mg/m2 over 2 hours)."	( A phase I trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma. Christos, P; Kaubisch, A; Ocean, AJ; Raab, R; Ramirez, M; Sparano, JA; Vinciguerra, V, 2010)	0.94

Excerpt	Relevance	Reference
" Dose-limiting reactions in phase I included hypotension and fever, and the MTD for phase II dosing was established at 3 mg/kg/d."	( Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. Cunningham, CC; Golenkov, AK; Novick, SC; O'Brien, SM; Rai, KR; Turkina, AG, 2005)	0.61
"To investigate whether irradiation before antisense Bcl-2 oligodeoxynucleotide (ODN) administration enhances tissue uptake, and whether periodic dosing enhances cellular uptake of fluorescently labeled ODN relative to constant dosing."	( Irradiation of human prostate cancer cells increases uptake of antisense oligodeoxynucleotide. Anai, S; Brown, BD; Goodison, S; Hirao, Y; Nakamura, K; Rosser, CJ, 2007)	0.34
" In addition, PC-3-Bcl-2 subcutaneous xenograft tumors were treated with or without irradiation in combination with various dosing schemas of G4243."	( Irradiation of human prostate cancer cells increases uptake of antisense oligodeoxynucleotide. Anai, S; Brown, BD; Goodison, S; Hirao, Y; Nakamura, K; Rosser, CJ, 2007)	0.34

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	2 (1.08)	18.2507
2000's	152 (81.72)	29.6817
2010's	25 (13.44)	24.3611
2020's	7 (3.76)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	40 (20.51%)	5.53%
Reviews	54 (27.69%)	6.00%
Case Studies	1 (0.51%)	4.05%
Observational	0 (0.00%)	0.25%
Other	100 (51.28%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (45)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase II Study of G3139 (Bcl-2 Antisense) And Rituximab in Patients With Recurrent B-cell Non-Hodgkinâs Lymphomas [NCT00054639]	Phase 2	48 participants (Actual)	Interventional	2003-01-31	Completed
A Phase I/II Study of Oblimersen in Combination With Cisplatin and Fluorouracil in Patients With Advanced Esophageal, Gastro-Esophageal Junction and Gastric Cancer [NCT00064259]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2003-06-30	Terminated(stopped due to Discontinued development of G3139 (oblimersen))
Investigator Initiated Pilot Study of Microarray Directed Therapy for Diffuse Large B-cell Lymphoma Using Genasense With CHOP-R [NCT00736450]	Early Phase 1	37 participants (Actual)	Interventional	2008-07-23	Terminated(stopped due to Manufacturer is no longer making the drug.)
A Phase IIA Study to Determine the Safety and Efficacy of A NCI-Supplied Agent: G3139 (NSC 683428, IND 58842) and Imatinib Mesylate in Patients With Refractory or Relapsed Gastrointestinal Stromal Tumor [NCT00091078]	Phase 2	96 participants (Actual)	Interventional	2005-09-30	Terminated
A Randomized Phase 3 Study of Fludarabine and Rituximab With or Without Genasense® (Oblimersen Sodium) in Previously Untreated Subjects With Chronic Lymphocytic Leukemia [NCT00517218]	Phase 3	0 participants	Interventional	2006-06-30	Withdrawn
A Phase II Study of G3139 (Genasense ™) in Patients With Merkel Cell Carcinoma [NCT00079131]	Phase 2	37 participants (Actual)	Interventional	2004-01-31	Completed
A Phase I Study Of Genasense, A Bcl-2 Antisense Oligonucleotide, Combined With Carboplatin And Etoposide In Patients With Small Cell Lung Cancer [NCT00017251]	Phase 1	12 participants (Actual)	Interventional	2001-04-30	Completed
Randomized Phase III Study of Dexamethasone With or Without Genasense (Bcl-2 Antisense Oligonucleotide) in Patients With Relapsed or Refractory Multiple Myeloma [NCT00017602]	Phase 3	0 participants	Interventional	2000-12-31	Completed
"A Pilot Study of Abraxane® (Albumin-bound Paclitaxel) and Temodar® (Temozolomide) Plus Genasense® (Oblimersen Sodium) in Subjects With Advanced Melanoma (The ATG Study)." [NCT00409383]	Phase 1	28 participants (Anticipated)	Interventional	2006-11-30	Active, not recruiting
A Randomized, Open-label, Cross-over Pharmacokinetic Study of Dacarbazine in Combination With Genasense® in Subjects With Advanced Melanoma [NCT00542893]	Phase 1	0 participants	Interventional	2006-04-30	Completed
A Pharmacokinetic Study of Genasense® (Bcl-2 Antisense Oligonucleotide) in Combination With Dacarbazine (DTIC) in Subjects With Advanced Melanoma and Normal or Impaired Hepatic Function [NCT00543205]	Phase 2/Phase 3	6 participants (Actual)	Interventional	2005-08-31	Terminated(stopped due to Terminated due to very slow enrollment)
A Phase 1/2 Study of Bcl-2 Antisense Oligonucleotide G3139 in Combination With Doxorubicin and Docetaxel in Metastatic and Locally Advanced Breast Cancer [NCT00063934]	Phase 1/Phase 2	31 participants (Actual)	Interventional	2003-05-31	Terminated
A Safety, Pharmacokinetic, and Pharmacodynamic Assessment of Genasense Administered as a 2-hour Intravenous Infusion to Subjects With Solid Tumors [NCT00636545]	Phase 1	25 participants (Actual)	Interventional	2007-05-31	Completed
Phase II Study of Genasense-Carboplatin-Paclitaxel-Combination in Uveal Melanoma [NCT01200342]	Phase 2	7 participants (Actual)	Interventional	2010-12-31	Terminated(stopped due to Pharmaceutical company no longer manufacturing investigational product.)
Randomized Phase II Trial of Docetaxel (Taxotere) and Oblimersen (Antisense Oligonucleotide Directed to BCL-2) Versus Taxotere Alone in Patients With Hormone-Refractory Prostate Cancer [NCT00085228]	Phase 2	116 participants (Actual)	Interventional	2004-04-30	Completed
A Phase I/II Study of G3139 (Genasense) in Combination With RICE Chemotherapy in Relapsed B-Cell Non-Hodgkin's Lymphoma [NCT00086944]	Phase 1/Phase 2	25 participants (Actual)	Interventional	2004-05-31	Completed
A Multicenter, Randomized, Double-blind Study of Dacarbazine With or Without Genasense in Chemotherapy-naive Subjects With Advanced Melanoma and Low LDH (The AGENDA Trial) [NCT00518895]	Phase 3	300 participants (Anticipated)	Interventional	2007-07-31	Completed
A Phase I Pharmacokinetic Study of Genasense® in Subjects With Normal Renal Function and Mildly and Moderately Impaired Renal Function [NCT00543075]	Phase 1	23 participants (Actual)	Interventional	2006-05-31	Completed
A Pharmacokinetic and Safety Assessment of G3139 Administered by Subcutaneous Injection to Patients With Solid Tumors [NCT00543231]	Phase 1	8 participants (Anticipated)	Interventional	2005-12-31	Completed
A Phase I/IIA Dose-Escalating Trial of BCL-2 Antisense (G3139) Treatment for Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumor Malignancies [NCT00003103]	Phase 1/Phase 2	57 participants (Anticipated)	Interventional	1997-08-31	Completed
Continuation Protocol For G3139 (Bcl-2 Antisense Oligonucleotide) And Dacarbazine In Patients With Malignant Melanoma Who Responded To This Combination In Protocol GM301 [NCT00070343]		0 participants	Interventional	2003-08-31	Active, not recruiting
A Phase II Trial of Rituximab + Oblimersen Sodium (GenasenseTM, G3139, NSC #683428, IND #58842) in Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL) [NCT00301795]	Phase 2	52 participants (Anticipated)	Interventional	2006-03-31	Terminated
A Phase I/Ib Study of BP1002 (a Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) [NCT05190471]	Phase 1	48 participants (Anticipated)	Interventional	2022-08-16	Recruiting
A Phase III Study of Daunorubicin and Cytarabine +/- G3139 (Genasense, Oblimersen Sodium, NSC #683428, IND #58842), a BCL2 Antisense Oligodeoxynucleotide, in Previously Untreated Patients With Acute Myeloid Leukemia (AML) > / = 60 Years [NCT00085124]	Phase 3	500 participants (Actual)	Interventional	2003-12-31	Completed
Randomized Study Of Dacarbazine Versus Dacarbazine Plus G3139 (Bcl-2 Antisense Oligonucleotide) In Patients With Advanced Malignant Melanoma [NCT00016263]	Phase 3	0 participants	Interventional	2000-07-31	Completed
A Phase I Trial Of G3139 (BCL-2 Antisense, NSC# 683428, IND# 58842) Combined With Cytotoxic Chemotherapy In Relapsed Childhood Solid Tumors [NCT00039481]	Phase 1	15 participants (Actual)	Interventional	2002-11-30	Completed
Phase II Study of Genasense (Bcl-2 Antisense) Combined With Mylotarg (Gemtuzumab Ozogamicin) in Elderly Patients With Relapsed Acute Myeloid Leukemia [NCT00017589]	Phase 2	0 participants	Interventional	2000-12-31	Completed
A PHASE II STUDY OF G3139 (GENASENSE™, NSC # 683428 IND # 58842) + IMATINIB MESYLATE (GLEEVEC®, STI571) IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA [NCT00049192]	Phase 2	43 participants (Anticipated)	Interventional	2002-11-30	Completed
A Phase I/II Study of Oblimersen Sodium (G3139, Genasense) in Combination With Oxaliplatin, 5FU and Leucovorin (FOLFOX4) Regimen in Advanced Colorectal Cancer [NCT00055822]	Phase 1/Phase 2	16 participants (Actual)	Interventional	2002-10-31	Completed
A Phase I Study of Oblimersen (Genasense™, G3139) in Combination With Gemcitabine in Advanced Malignancies [NCT00060112]	Phase 1	15 participants (Actual)	Interventional	2003-03-31	Terminated(stopped due to Administratively complete.)
A Phase I Study of G3139 ( NSC # 683428) in Combination With Cytarabine and Daunorubicin in Previously Untreated Patients With Acute Myeloid Leukemia (AML)>= 60 Years of Age [NCT00039117]	Phase 1	32 participants (Actual)	Interventional	2002-04-30	Completed
A Phase II Study Of Genasense In Combination With Thalidomide And Dexamethasone In Relapsed And Refractory Multiple Myeloma [NCT00049374]	Phase 2	0 participants	Interventional	2002-09-30	Completed
Randomized Study Of Fludarabine And Cyclophosphamide With Or Without Genasense (Bcl-2 Antisense Oligonucleotide) In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia [NCT00024440]	Phase 3	0 participants	Interventional	2001-07-31	Completed
Randomized Study of Docetaxel Versus Docetaxel Plus Genasense™ (G3139; Bcl-2 Antisense Oligonucleotide) in Patients With Previously Treated Non-Small Cell Lung Cancer [NCT00030641]	Phase 2/Phase 3	0 participants	Interventional	2001-10-31	Active, not recruiting
Phase I/II Study of G3139 (Genasense) in Patients With Waldenstrom's Macroglobulinemia [NCT00062244]	Phase 1/Phase 2	58 participants (Actual)	Interventional	2003-05-31	Completed
A Phase I Study Of G3139 Antisense Oligonucleotide (Oblimersen) In Combination With CHOP And Rituximab In Untreated Advanced Stage Diffuse Large B Cell Lymphoma [NCT00070083]	Phase 1	0 participants	Interventional	2003-07-31	Completed
A Pilot Study of Genasense® (G3139, Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated Subjects With Chronic Lymphocytic Leukemia [NCT00078234]	Phase 1/Phase 2	25 participants (Actual)	Interventional	2003-11-30	Completed
Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab, or Rituximab and G3139 Phosphorothioate Oligonucleotide (BCL-2 Antisense - NSC-683428) Therapy for Young Patients (< Age 60) With Advanced Stage Diffuse Large B-Cel [NCT00080847]	Phase 2	160 participants (Actual)	Interventional	2004-03-31	Terminated
A Randomized Phase II Study Of Carboplatin And Etoposide With Or Without G3139 (NSC #683428, IND #58842) In Patients With Extensive Stage Small Cell Lung Cancer [NCT00042978]	Phase 2	55 participants (Actual)	Interventional	2003-04-30	Completed
A Phase I Study of Antisense Bcl-2 Oligonucleotide (G3139) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors [NCT00054548]	Phase 1	55 participants (Actual)	Interventional	2002-10-31	Completed
A Phase II Study of G3139 in Combination With Doxorubicin in Advanced Hepatocellular Carcinoma [NCT00047229]	Phase 2	27 participants (Actual)	Interventional	2002-10-31	Completed
A Phase II Trial of G3139 (Genasense) Anti-Bcl-2 Antisense Oligonucleotide Plus Alpha-Interferon in Metastatic Renal Cancer [NCT00059813]	Phase 2	41 participants (Anticipated)	Interventional	2003-08-31	Completed
A Phase I/II, Pharmacokinetic, and Biologic Correlative Study of G3139, NSC # 683428 (Phosphorothioate Antisense Oligonucleotide Directed to Bcl-2) and Irinotecan in Patients With Metastatic Colorectal Cancer [NCT00004870]	Phase 1/Phase 2	0 participants	Interventional	2000-06-30	Completed
A Phase I/II Study of G3139, a BCL-2 Antisense Oligonucleotide, Combined With Paclitaxel for the Treatment of Recurrent Small Cell Lung Cancer [NCT00005032]	Phase 1/Phase 2	12 participants (Actual)	Interventional	2000-04-30	Completed
A Phase I Study of G3139 (NSC 683428) in Combination With Salvage Chemotherapy for Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) [NCT00004862]	Phase 1	24 participants (Actual)	Interventional	1999-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00054639 (1) [back to overview]	Number of Patients With Objective Response
NCT00063934 (4) [back to overview]	Bcl-2 Expression in Breast Cancer Tissue
NCT00063934 (4) [back to overview]	Number of Participant With Toxicities
NCT00063934 (4) [back to overview]	Number of Participants With Pathologic Complete Response (pCR)
NCT00063934 (4) [back to overview]	Clinical Imaging Responses
NCT00064259 (1) [back to overview]	Maximum Tolerated Dose (MTD) of Oblimersen in Combination With Cisplatin and 5-FU
NCT00736450 (2) [back to overview]	Time to Perform Microarray Study After Receipt of Tissue
NCT00736450 (2) [back to overview]	Number of Participants With Microarray Testing Results Are Completed Within 7 Days.
NCT01200342 (2) [back to overview]	Overall Response Rate (Percentage Subjects With Confirmed Complete or Partial Response)
NCT01200342 (2) [back to overview]	Number of Participants With Response

Number of Patients With Objective Response

Efficacy as measured by objective response complete (CR) and partial (PR) response rates at 2 months following study treatment (NCT00054639)
Timeframe: 2 months following study treatment

Intervention	participants (Number)
	Complete Responses	Partial Responses
Oblimersen + Rituximab	10	8

[back to top]

Bcl-2 Expression in Breast Cancer Tissue

Number of participant with Bcl-2 Expression in breast cancer tissue by protein and mRNA expression before treatment and at 3-5 days after oblimersen treatment. (NCT00063934)
Timeframe: before treatment and at 3-5 days after oblimersen treatment

Intervention	participants (Number)
Oblimersen Plus Doxorubicin + Docetaxel	30

[back to top]

Number of Participant With Toxicities

(NCT00063934)
Timeframe: From baseline until the date of first documented toxicity or date of death from any cause, whichever came first, assessed every three weeks up to 2 years and 5 months

Intervention	Participants (Count of Participants)
Oblimersen Plus Doxorubicin + Docetaxel	30

[back to top]

Number of Participants With Pathologic Complete Response (pCR)

Pathologic complete responses (pCR), defined as no evidence of residual invasive tumor, including no residual tumor in the axillary lymph nodes, measured by microscopic evaluation of tissue specimen at time of definitive surgery (after 6 courses of neoadjuvant therapy). Neoadjuvant (preoperative) therapy administered on the first five days of every 3-week cycle. Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3):205-216, 2000] (NCT00063934)
Timeframe: At time of definitive surgery (after 6 courses of neoadjuvant therapy in 3 week cycles), approximately 18 weeks

Intervention	Participants (Number)
Oblimersen Plus Doxorubicin + Docetaxel	0

[back to top]

Clinical Imaging Responses

Evaluation target lesions (clinical response) by physical exam/ultrasound measurements of primary tumor and axillary lymph nodes after 3-6 courses: Complete Response: Disappearance of all target lesions; Partial Response: >30% decrease in sum longest diameter (LD) of target lesions, reference baseline sum LD; Progressive Disease: >20% increase in sum of LD of target lesions, reference smallest sum LD recorded since treatment started or appearance of 1>new lesions; Stable Disease: Neither sufficient shrinkage for PR nor increase for PD, reference smallest sum LD since treatment started. (NCT00063934)
Timeframe: After 3 and 6 courses of 21 day treatments (up to 18 weeks)

Intervention	participants (Number)
	CR	PR
Oblimersen Plus Doxorubicin + Docetaxel	30	0

[back to top]

Maximum Tolerated Dose (MTD) of Oblimersen in Combination With Cisplatin and 5-FU

Adverse events were evaluated according to the National Cancer Institute Common Toxicity Criteria (version 2.0). DLT was defined as grade 3 to 4 hematologic toxicity lasting more than 1 week after 5-FU/cisplatin, grade 3 to 4 nausea or vomiting occurring later than 11 days after cisplatin, grade 3 to 4 diarrhea occurring later than 10 days after 5-FU, and grade 3 to 4 mucositis at the beginning of the next cycle. (NCT00064259)
Timeframe: 21 days

Intervention	mg/kg/d (Number)
Oblimersen + Cisplatin + 5-FU	5

[back to top]

Time to Perform Microarray Study After Receipt of Tissue

The time from tissue harvest to release of microarray test and IHC assay results will be noted in days. (NCT00736450)
Timeframe: Upto 14 days

Intervention	days (Mean)
Arm I	4.4

[back to top]

Number of Participants With Microarray Testing Results Are Completed Within 7 Days.

(NCT00736450)
Timeframe: Upto 7 days

Intervention	Participants (Count of Participants)
	results within 7 days or less	results in more than 7 days
Arm I	11	2

[back to top]

Overall Response Rate (Percentage Subjects With Confirmed Complete or Partial Response)

Tumor response by Response Evaluation Criteria in Solid Tumors for participants with measurable disease defined by presence of at least 1 measurable lesion at baseline: Complete Response (CR): disappearance all target lesions determined by 2 consecutive observations not less than 4 weeks apart. Partial Response (PR): >30% decrease in sum of LD of target lesions (LD) of target lesions taking as reference baseline sum LD determined by two consecutive observations not less than four weeks apart. Progression (PD): >20% increase in sum of LD of target lesions references smallest sum LD recorded since treatment started or appearance of one or more new lesions. Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking references smallest sum LD since treatment started. Measurable: lesions accurately measured in at least 1 dimension (longest diameter to be recorded) as 20 mm with conventional techniques or as 10 mm with spiral CT s (NCT01200342)
Timeframe: Following two 3-week cycles

Intervention	Percentage of Participants (Number)
Genasense + Paclitaxel + Carboplatin	0

[back to top]

Number of Participants With Response

Intervention	Participants (Number)
	Complete Response (CR)	Partial Response (PR)	Progressive Disease (PD)	Stable Disease (SD)
Genasense + Paclitaxel + Carboplatin	0	0	1	6

[back to top]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
cytosine [no description available]	4.32	3	0	aminopyrimidine; pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	3.54	2	0	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
thymine [no description available]	2.03	1	0	pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite
uracil 2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder	2.03	1	0	pyrimidine nucleobase; pyrimidone	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; prodrug; Saccharomyces cerevisiae metabolite
pk 11195 PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine	2.11	1	0	aromatic amide; isoquinolines; monocarboxylic acid amide; monochlorobenzenes	antineoplastic agent
anastrozole [no description available]	3.12	1	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
chelerythrine chelerythrine : A benzophenanthridine alkaloid isolated from the root of Zanthoxylum simulans, Chelidonium majus L., and other Papaveraceae.	3.13	1	0	benzophenanthridine alkaloid; organic cation	antibacterial agent; antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	10.84	2	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
gossypol Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.	5.38	5	0
ha14-1 ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate: a BH3 mimetic; synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia	2.02	1	0	1-benzopyran
letrozole [no description available]	3.12	1	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	3.81	2	1	dihydroxyanthraquinone	analgesic; antineoplastic agent
temozolomide [no description available]	10.21	3	1	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
thalidomide Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.	6.63	3	1	phthalimides; piperidones
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	3.12	1	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
glutamine Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.	2.03	1	0	amino acid zwitterion; glutamine family amino acid; glutamine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
adenosine diphosphate Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.	2.03	1	0	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
bromodeoxyuridine Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.	2.01	1	0	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
carbostyril Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.	4.03	2	0	monohydroxyquinoline; quinolone	bacterial xenobiotic metabolite
cytidine [no description available]	2.21	1	0	cytidines	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
cytarabine [no description available]	5.61	3	2	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
trifluridine Trifluridine: An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557). trifluridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis.	2.03	1	0	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; EC 2.1.1.45 (thymidylate synthase) inhibitor
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	5.87	6	0	pyrrole; secondary amine
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	4.66	3	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	3.19	1	0	indazole
thiazoles [no description available]	2.02	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	5.79	4	0	diazine; pyrazines	Daphnia magna metabolite
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	3.11	1	0	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
deoxycytidine [no description available]	5.43	4	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
arsenic trioxide Arsenic Trioxide: An inorganic compound with the chemical formula As2O3 that is used for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA in patients who have relapsed from, or are resistant to, conventional drug therapy.	3.12	1	0
vidarabine adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.	7.93	5	3	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	4.1	3	1	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	3.83	2	1	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
fludarabine phosphate fludarabine phosphate: structure given in first source. fludarabine phosphate : A purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. A prodrug, it is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. Once incorporated into DNA, 2-fluoro-ara-ATP functions as a DNA chain terminator. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to, or whose disease has progressed during, treatment with at least one standard alkylating-agent containing regimenas.	3.12	1	0	nucleoside analogue; organofluorine compound; purine arabinonucleoside monophosphate	antimetabolite; antineoplastic agent; antiviral agent; DNA synthesis inhibitor; immunosuppressive agent; prodrug
transferrin Transferrin: An iron-binding beta1-globulin that is synthesized in the LIVER and secreted into the blood. It plays a central role in the transport of IRON throughout the circulation. A variety of transferrin isoforms exist in humans, including some that are considered markers for specific disease states.	2.05	1	0
vidarabine phosphate Vidarabine Phosphate: An adenosine monophosphate analog in which ribose is replaced by an arabinose moiety. It is the monophosphate ester of VIDARABINE with antiviral and possibly antineoplastic properties.	3.12	1	0
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	12.11	9	4	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	10.76	3	2	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
simvastatin Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.	2.03	1	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug
aromasil [no description available]	3.12	1	0	17-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor; environmental contaminant; xenobiotic
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	9.11	3	1	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
irinotecan [no description available]	8.41	1	1	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
capecitabine Capecitabine: A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.. capecitabine : A carbamate ester that is cytidine in which the hydrogen at position 5 is replaced by fluorine and in which the amino group attached to position 4 is converted into its N-(penyloxy)carbonyl derivative. Capecitabine is a antineoplastic agent used in the treatment of cancers.	3.12	1	0	carbamate ester; cytidines; organofluorine compound	antimetabolite; antineoplastic agent; prodrug
thiazolyl blue thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.	2.02	1	0	organic bromide salt	colorimetric reagent; dye
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	3.12	1	0	1,2,3-triazole
7-hydroxystaurosporine [no description available]	3.11	1	0
bendamustine hydrochloride [no description available]	4.67	3	0
fulvestrant Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.	3.12	1	0	17beta-hydroxy steroid; 3-hydroxy steroid; organofluorine compound; sulfoxide	antineoplastic agent; estrogen antagonist; estrogen receptor antagonist
clofarabine [no description available]	4.02	2	0	adenosines; organofluorine compound	antimetabolite; antineoplastic agent
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	12.2	7	1	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
gefitinib [no description available]	4.66	3	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	9.78	14	8	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
lonafarnib lonafarnib: inhibitor of farnesyl protein transferase. lonafarnib : A 4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamide that has R configuration. It is used as oral farnesyltransferase inhibitor.	3.12	1	0	4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamide	antineoplastic agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor
vatalanib [no description available]	3.11	1	0	monochlorobenzenes; phthalazines; pyridines; secondary amino compound	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
phosphorodithioic acid dithiophosphoric acid : A phosphorothioic acid that is the phosphoric acid having two of its oxygen atoms replaced by sulfur atoms.	2.44	2	0	phosphorothioic acid
tipifarnib [no description available]	4.03	2	0	imidazoles; monochlorobenzenes; primary amino compound; quinolone	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor
atrasentan Atrasentan: A pyrrolidine and benzodioxole derivative that acts a RECEPTOR, ENDOTHELIN A antagonist. It has therapeutic potential as an antineoplastic agent and for the treatment of DIABETIC NEPHROPATHIES.	3.54	2	0	pyrrolidines
sorafenib [no description available]	3.54	2	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
lenalidomide [no description available]	3.14	1	0	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator
gossypol acetic acid [no description available]	4.14	2	0
bortezomib [no description available]	10.79	4	0	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
carboplatin [no description available]	10.03	3	3
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	3.51	2	0	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
pectins Pectins: High molecular weight polysaccharides present in the cell walls of all plants. Pectins cement cell walls together. They are used as emulsifiers and stabilizers in the food industry. They have been tried for a variety of therapeutic uses including as antidiarrheals, where they are now generally considered ineffective, and in the treatment of hypercholesterolemia.. alpha-D-galacturonic acid : The alpha-anomer of D-galacturonic acid.	3.12	1	0	D-galactopyranuronic acid
thapsigargin Thapsigargin: A sesquiterpene lactone found in roots of THAPSIA. It inhibits SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES.. thapsigargin : An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations.	2.02	1	0	butyrate ester; organic heterotricyclic compound; sesquiterpene lactone	calcium channel blocker; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
epothilone a Epothilones: A group of 16-member MACROLIDES which stabilize MICROTUBULES in a manner similar to PACLITAXEL. They were originally found in the myxobacterium Sorangium cellulosum, now renamed to Polyangium (MYXOCOCCALES).	3.13	1	0	epothilone; epoxide	antineoplastic agent; metabolite; microtubule-stabilising agent; tubulin modulator
decitabine [no description available]	3.11	1	0	2'-deoxyribonucleoside
troxacitabine troxacitabine: shows good anti-HIV activity without cytotoxicity	4.02	2	0	carbohydrate derivative; nucleobase-containing molecular entity
s 1033 [no description available]	2.03	1	0	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
leuprolide Leuprolide: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.. leuprolide : An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.	3.12	1	0	oligopeptide	anti-estrogen; antineoplastic agent; gonadotropin releasing hormone agonist
fludarabine [no description available]	7.4	4	2	purine nucleoside
ovalbumin Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.	2.08	1	0
calcitriol dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes	3.54	2	0	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	2.04	1	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
alvocidib alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.	4.04	2	0	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
semaxinib semaxanib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is replaced by a 3,5-dimethylpyrrol-2-yl group.	3.11	1	0	olefinic compound; oxindoles; pyrroles	angiogenesis modulating agent; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
arsenic Arsenic: A shiny gray element with atomic symbol As, atomic number 33, and atomic weight 75. It occurs throughout the universe, mostly in the form of metallic arsenides. Most forms are toxic. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), arsenic and certain arsenic compounds have been listed as known carcinogens. (From Merck Index, 11th ed)	3.12	1	0	metalloid atom; pnictogen	micronutrient
4-heptadecylumbelliferone 4-heptadecylumbelliferone: fluorescence pH indicator	2	1	0
carbocyanines Carbocyanines: Compounds that contain three methine groups. They are frequently used as cationic dyes used for differential staining of biological materials.	2.07	1	0	cyanine dye; organic iodide salt	fluorochrome
1,2-dioleoyloxy-3-(trimethylammonium)propane 1,2-dioleoyloxy-3-(trimethylammonium)propane: fluorescent probe for phospholipids; RN & structure given in first source	2	1	0
ixabepilone [no description available]	3.13	1	0	1,3-thiazoles; beta-hydroxy ketone; epoxide; lactam; macrocycle	antineoplastic agent; microtubule-destabilising agent
staurosporine staurosporinium : Conjugate acid of staurosporine.	3.11	1	0	ammonium ion derivative
taxane taxane: produced by Taxomyces andreanae	3.41	1	1	diterpene; terpenoid fundamental parent
st 1481 ST 1481: structure in first source	2.02	1	0
pazopanib pazopanib: a protein kinase inhibitor. pazopanib : A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.	3.19	1	0	aminopyrimidine; indazoles; sulfonamide	angiogenesis modulating agent; antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
erastin erastin: an antineoplastic agent; structure in first source. erastin : A member of the class of quinazolines that is quinazolin-4(3H)-one in which the hydrogens at positions 2 and 3 are replaced by 1-{4-[(4-chlorophenoxy)acetyl]piperazin-1-yl}ethyl and 2-ethoxyphenyl groups, respectively. It is an inhibitor of voltage-dependent anion-selective channels (VDAC2 and VDAC3) and a potent ferroptosis inducer.	2.6	1	0	aromatic ether; diether; monochlorobenzenes; N-acylpiperazine; N-alkylpiperazine; quinazolines; tertiary carboxamide	antineoplastic agent; ferroptosis inducer; voltage-dependent anion channel inhibitor
abt-737 [no description available]	6.01	7	0	aromatic amine; aryl sulfide; biphenyls; C-nitro compound; monochlorobenzenes; N-arylpiperazine; N-sulfonylcarboxamide; secondary amino compound; tertiary amino compound	anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.	3.28	6	0
abarelix abarelix: RN & structure in first source. abarelix : A polypeptide compound composed of ten natural and non-natural amino acid resiudes in a linear sequence.	3.12	1	0	polypeptide	antineoplastic agent; hormone antagonist
oligonucleotides [no description available]	5.26	9	0
navitoclax [no description available]	5.58	5	0	aryl sulfide; monochlorobenzenes; morpholines; N-sulfonylcarboxamide; organofluorine compound; piperazines; secondary amino compound; sulfone; tertiary amino compound	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
piperidines Piperidines: A family of hexahydropyridines.	4.66	3	0
gx 15-070 obatoclax: a pan-Bcl-2 inhibitor potentially useful in treating mantle cell lymphoma	5.56	5	0
abt-199 venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.. venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.	3.25	1	0	aromatic ether; C-nitro compound; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; N-sulfonylcarboxamide; oxanes; pyrrolopyridine	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
agar Agar: A complex sulfated polymer of galactose units, extracted from Gelidium cartilagineum, Gracilaria confervoides, and related red algae. It is used as a gel in the preparation of solid culture media for microorganisms, as a bulk laxative, in making emulsions, and as a supporting medium for immunodiffusion and immunoelectrophoresis.. agar : A complex mixture of polysaccharides extracted from species of red algae. Its two main components are agarose and agaropectin. Agarose is the component responsible for the high-strength gelling properties of agar, while agaropectin provides the viscous properties.	2.01	1	0
cyclin d1 Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.	2.03	1	0
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone: an interleukin-1beta converting enzyme (ICE)-like protease inhibitor	2.03	1	0
nitrophenols Nitrophenols: PHENOLS carrying nitro group substituents.	6.01	7	0
lipofectamine Lipofectamine: mediates gene transfer; a polycationic lipid reagent	2.02	1	0
aprinocarsen ISIS 3521: 20-nucleotide phosphorothioate antisense molecule that targets protein kinase C-alpha isoenzyme	4.31	3	0
guanine [no description available]	2.02	1	0	2-aminopurines; oxopurine; purine nucleobase	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
guanosine ribonucleoside : Any nucleoside where the sugar component is D-ribose.	2.01	1	0	guanosines; purines D-ribonucleoside	fundamental metabolite
dacarbazine (E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.	10.48	13	6	dacarbazine
4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one [no description available]	2.02	1	0

Condition	Relationship Strength	Studies	Trials
Acute Myelogenous Leukemia [description not available]	7.58	7	3
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	7.58	7	3
Alcohol Abuse [description not available]	2.6	1	0
Alcoholism A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)	2.6	1	0
Breast Cancer [description not available]	7.93	13	4
Breast Neoplasms Tumors or cancer of the human BREAST.	7.93	13	4
B-Cell Lymphoma [description not available]	11.84	5	1
Lymphoma, B-Cell A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.	6.84	5	1
Apolipoprotein B-100, Familial Defective [description not available]	2.08	1	0
Hyperlipoproteinemia Type II A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).	2.08	1	0
Asthma, Bronchial [description not available]	2.08	1	0
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	2.08	1	0
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	2.08	1	0
Bronchial Hyperreactivity Tendency of the smooth muscle of the tracheobronchial tree to contract more intensely in response to a given stimulus than it does in the response seen in normal individuals. This condition is present in virtually all symptomatic patients with asthma. The most prominent manifestation of this smooth muscle contraction is a decrease in airway caliber that can be readily measured in the pulmonary function laboratory.	2.08	1	0
Bladder Cancer [description not available]	2.44	2	0
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	2.44	2	0
Malignant Melanoma [description not available]	13.77	36	12
Cancer of Skin [description not available]	12.64	22	13
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	13.77	36	12
Skin Neoplasms Tumors or cancer of the SKIN.	12.64	22	13
Polyomavirus Infections Infections with POLYOMAVIRUS, which are often cultured from the urine of kidney transplant patients. Excretion of BK VIRUS is associated with ureteral strictures and CYSTITIS, and that of JC VIRUS with progressive multifocal leukoencephalopathy (LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL).	3.01	1	0
Lymph Node Metastasis [description not available]	3.01	1	0
Merkel Cell Cancer [description not available]	5.03	3	1
Carcinoma, Merkel Cell A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)	5.03	3	1
Cancer of Lung [description not available]	8.5	12	3
Lung Neoplasms Tumors or cancer of the LUNG.	8.5	12	3
B-Cell Chronic Lymphocytic Leukemia [description not available]	10.9	15	3
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	4.78	2	1
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	10.9	15	3
Leucocythaemia [description not available]	5.42	5	1
Germinoblastoma [description not available]	3.34	2	0
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	5.42	5	1
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	3.34	2	0
Cancer of Prostate [description not available]	9.91	18	5
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	9.91	18	5
Granulocytic Leukemia, Chronic [description not available]	5.24	4	1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	5.24	4	1
Recrudescence [description not available]	7.22	4	4
Benign Neoplasms [description not available]	10.78	29	5
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	10.78	29	5
Metastase [description not available]	6.9	7	4
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	6.9	7	4
Kahler Disease [description not available]	8.45	7	2
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	13.45	7	2
Lassitude [description not available]	4.35	1	1
Pyrexia [description not available]	4.35	1	1
Fatigue The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.	4.35	1	1
Fever An abnormal elevation of body temperature, usually as a result of a pathologic process.	4.35	1	1
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	4.35	1	1
Cancer of Liver [description not available]	5.78	2	2
Liver Neoplasms Tumors or cancer of the LIVER.	5.78	2	2
Local Neoplasm Recurrence [description not available]	6.5	3	2
Cancer of Esophagus [description not available]	4.36	1	1
Cancer of Stomach [description not available]	4.74	2	1
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	4.36	1	1
Stomach Neoplasms Tumors or cancer of the STOMACH.	4.74	2	1
Minimal Disease, Residual [description not available]	2.96	1	0
Carcinoma, Oat Cell [description not available]	8.23	9	3
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	8.23	9	3
Genito-urinary Cancer [description not available]	3	1	0
Urogenital Neoplasms Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female.	3	1	0
Granulocytic Leukemia [description not available]	7.65	7	2
Acute Disease Disease having a short and relatively severe course.	8.01	7	3
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	7.65	7	2
Hematologic Malignancies [description not available]	3.81	2	0
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	5.54	7	0
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	5.54	7	0
Hematologic Neoplasms Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.	3.81	2	0
Cytomegaloviral Retinitis [description not available]	2.01	1	0
Cytomegalovirus Retinitis Infection of the retina by cytomegalovirus characterized by retinal necrosis, hemorrhage, vessel sheathing, and retinal edema. Cytomegalovirus retinitis is a major opportunistic infection in AIDS patients and can cause blindness.	2.01	1	0
Disease Exacerbation [description not available]	10.27	13	11
Familial Waldenstrom's Macroglobulinaemia [description not available]	5.01	3	1
Waldenstrom Macroglobulinemia A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.	5.01	3	1
EBV Infections [description not available]	2.01	1	0
Duncan Disease [description not available]	3.34	2	0
Lymphoproliferative Disorders Disorders characterized by proliferation of lymphoid tissue, general or unspecified.	3.34	2	0
Epstein-Barr Virus Infections Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).	2.01	1	0
Acute Promyelocytic Leukemia [description not available]	2.01	1	0
Leukemia, Promyelocytic, Acute An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.	2.01	1	0
Abnormalities, Autosome [description not available]	2.93	1	0
Adenocarcinoma Of Kidney [description not available]	2.02	1	0
Cancer of Kidney [description not available]	4.1	3	1
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	2.02	1	0
Kidney Neoplasms Tumors or cancers of the KIDNEY.	4.1	3	1
Carcinoma, Non-Small Cell Lung [description not available]	3.34	2	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	3.34	2	0
Cancer of Ovary [description not available]	2.71	3	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.71	3	0
Angiogenesis, Pathologic [description not available]	3.35	2	0
Lymphocytopenia [description not available]	3.41	1	1
Colorectal Cancer [description not available]	10.02	3	1
Lymphopenia Reduction in the number of lymphocytes.	3.41	1	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	5.02	3	1
Carcinoma, Anaplastic [description not available]	2.72	3	0
Cancer of Nasopharynx [description not available]	2.03	1	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	2.72	3	0
Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX.	2.03	1	0
Adenocarcinoma, Basal Cell [description not available]	3.35	2	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	3.35	2	0
Adverse Drug Event [description not available]	4.33	1	1
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	4.33	1	1
Female Genital Neoplasms [description not available]	2.94	1	0
Genital Neoplasms, Female Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).	2.94	1	0
Aggressive Systemic Mastocytosis A form of systemic mastocytosis in which patients have impaired organ functions due to multifocal infiltrates of pathological MAST CELLS in bone marrow, liver, spleen, gastrointestinal tract, or skeletal system. The cytomorphology shows a low to high grade.	2.03	1	0
Mastocytosis, Systemic A group of disorders caused by the abnormal proliferation of MAST CELLS in a variety of extracutaneous tissues including bone marrow, liver, spleen, lymph nodes, and gastrointestinal tract. Systemic mastocytosis is commonly seen in adults. These diseases are categorized on the basis of clinical features, pathologic findings, and prognosis.	2.03	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	4.1	3	0
Nerve Degeneration Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.	2.03	1	0
HIV Coinfection [description not available]	2.03	1	0
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	2.03	1	0
Genetic Diseases [description not available]	2.94	1	0
Viral Diseases [description not available]	2.94	1	0
HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.	2.94	1	0
Virus Diseases A general term for diseases caused by viruses.	2.94	1	0
Genetic Diseases, Inborn Diseases that are caused by genetic mutations present during embryo or fetal development, although they may be observed later in life. The mutations may be inherited from a parent's genome or they may be acquired in utero.	2.94	1	0
B16 Melanoma [description not available]	2.03	1	0
Blood Diseases [description not available]	4.34	1	1
Hepatocellular Carcinoma [description not available]	9.34	1	1
Hematologic Diseases Disorders of the blood and blood forming tissues.	4.34	1	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	4.34	1	1
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated [description not available]	2.04	1	0
Lymphoma, Mantle-Cell A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).	2.04	1	0
Acute Lymphoid Leukemia [description not available]	2.04	1	0
Chromosomal Translocation [description not available]	2.04	1	0
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	2.04	1	0
Carcinoma, Ductal, Breast An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.	3.43	1	1
Brill-Symmers Disease [description not available]	2.91	1	0
Lymphoma, Follicular Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.	2.91	1	0

oblimersen

Description

Cross-References

Synonyms (12)

Research Excerpts

Overview

Actions

Treatment

Pharmacokinetics

Compound-Compound Interactions

Dosage Studied

Research

Studies (186)

Market Indicators

Research Demand Index: 30.67

Study Types

Clinical Trials (45)

Trial Overview

Trial Outcomes

Number of Patients With Objective Response

Bcl-2 Expression in Breast Cancer Tissue

Number of Participant With Toxicities

Number of Participants With Pathologic Complete Response (pCR)

Clinical Imaging Responses

Maximum Tolerated Dose (MTD) of Oblimersen in Combination With Cisplatin and 5-FU

Time to Perform Microarray Study After Receipt of Tissue

Number of Participants With Microarray Testing Results Are Completed Within 7 Days.

Overall Response Rate (Percentage Subjects With Confirmed Complete or Partial Response)

Number of Participants With Response

oblimersen

Description

Cross-References

Synonyms (12)

Research Excerpts

Overview

Actions

Treatment

Pharmacokinetics

Compound-Compound Interactions

Dosage Studied

Research

Studies (186)

Market Indicators

Research Demand Index: 30.67

Study Types

Clinical Trials (45)

Trial Overview

Trial Outcomes

Number of Patients With Objective Response

Bcl-2 Expression in Breast Cancer Tissue

Number of Participant With Toxicities

Number of Participants With Pathologic Complete Response (pCR)

Clinical Imaging Responses

Maximum Tolerated Dose (MTD) of Oblimersen in Combination With Cisplatin and 5-FU

Time to Perform Microarray Study After Receipt of Tissue

Number of Participants With Microarray Testing Results Are Completed Within 7 Days.

Overall Response Rate (Percentage Subjects With Confirmed Complete or Partial Response)

Number of Participants With Response

Related Drugs (104)

Related Conditions (127)